Also, these studies generally use the maximum tolerated dose of the drug that is many times the human therapeutic one. Human experience in ordinary diets is quite different. Such studies are more appropriate for a new drug than for a new use of an approved drug with a long history of safe utilization. There is extensive experience in oral use of quinacrine in humans as an antimalarial, helvetica with no report of cancer from this. If any increased risk of cancer exists with oral use it must be small.
Transcervical administration involves a much lower dose than for malaria prophylaxis or treatment.
We know that chronic inflammation is associated with increased risk of cancer, as in hepatitis B for cancer of the liver. Actually, no drug given once or twice in a person's lifetime at a therapeutic dose has ever been reported to cause cancer. It is clear that for most developing countries benefits of QS outweigh the risks. At this time additional clinical trials are required to confirm leads for the improved efficacy of QS and for large field trials to further document its safety and acceptability in various settings. 31,781 cases of nonsurgical female sterilization with quinacrine pellets in Vietnam.